Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Breast Cancer Genetics, Immunology, and Immunotherapy : an Interdisciplinary Approach
| Breast Cancer Genetics, Immunology, and Immunotherapy : an Interdisciplinary Approach |
| Autore | Rezaei Nima |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Cham : , : Springer, , 2024 |
| Descrizione fisica | 1 online resource (436 pages) |
| Collana | Interdisciplinary Cancer Research Series |
| ISBN |
9783031658082
9783031658075 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910874677603321 |
Rezaei Nima
|
||
| Cham : , : Springer, , 2024 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Breast Cancer Pathophysiology
| Breast Cancer Pathophysiology |
| Autore | Rezaei Nima |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Cham : , : Springer, , 2024 |
| Descrizione fisica | 1 online resource (330 pages) |
| Collana | Interdisciplinary Cancer Research Series |
| ISBN | 9783031658358 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Preface -- Contents -- About the Editor -- Interdisciplinary Approach in Breast Cancer -- 1 Introduction -- 2 Interdisciplinary Approach in Breast Cancer -- 2.1 Screening and Diagnosis -- 2.2 Pathology -- 2.3 Surgery -- 2.4 Chemotherapy -- 2.5 Radiotherapy -- 2.6 Hormone Therapy -- 2.7 Targeted Therapy -- 2.7.1 Human Epidermal Growth Factor Receptors (HER1 and HER2) Inhibitors -- 2.7.2 VEGF Inhibitors -- 2.7.3 CDK4/6 Inhibitors -- 2.7.4 mTOR Inhibitors -- 2.7.5 Histone Deacetylase (HDAC) Inhibitors -- 2.7.6 PARP Inhibitors -- 2.7.7 Targeting Tumor Microenvironment -- 2.8 Immunotherapy -- 2.9 Relieving Physical and Psychological Symptoms -- 3 Advances in Molecular Tests -- 4 Conclusion -- References -- Circulating Tumor Cells in Breast Cancer -- 1 Introduction -- 2 Breast Cancer Risk Factors and Epidemiology -- 2.1 Risk Factors and Screening -- 2.2 Diagnosis -- 2.3 Biological Subtypes -- 3 Routes to Metastasis and the Role of Circulating Tumor Cells -- 3.1 Pre-metastatic Niche (PMN) Formation -- 3.2 Different Models of Metastatic Cascade in BC -- 3.2.1 Linear Progression -- 3.2.2 Parallel Progression -- 3.3 Hematogenous Dissemination Is Driven by Circulating Tumor Cells -- 3.3.1 Genetic Changes in CTCs -- 3.3.2 Phenotypic Changes in CTCs -- Metabolic Re-programming -- Cytoskeletal Re-organization to Withstand Deformations and Change Adherence -- Epithelial-to-Mesenchymal Transition (EMT) -- Clustering -- Masking Against Immune Attack -- 4 Metastatic Seeding -- 5 Dormancy -- Disseminated Tumor Cells -- 6 Types and Biology of CTCs and CTC Clusters -- 6.1 Single CTCs -- 6.2 CTC Clusters -- 6.2.1 Types of Clusters -- Homotypic Clusters -- Heterotypic Clusters -- Stromal Cells -- Immune Cells -- 6.2.2 Origin of CTC Clusters -- 7 Methods of CTC Detection -- 8 Clinical Applications -- 8.1 The Concept of Liquid Biopsy (CTC, cfDNA).
8.2 CTCs as Prognostic Factor -- 9 Conclusion -- References -- Breast Cancer Cells Extravasation Across the Blood-Brain Barrier: From Basic to Translational Research -- 1 Introduction -- 2 Breast Cancer Development: The Beginning of the End -- 2.1 Metastatic Breast Cancer: Focus on Brain Metastases -- 2.2 Going to the Brain: Metastatic Cascade -- 3 Endothelium-Malignant Cells Interaction: A Key Step for Extravasation -- 3.1 Blood-Brain Barrier: A Big Challenge for Brain Metastasization -- 3.2 Adhesion of Tumour Cells to the Blood-Brain Barrier Endothelium -- 3.2.1 Selectins and Their Ligands Promote the Rolling and Initial Attachment to Endothelium -- 3.2.2 Integrins-IgCAMs Complexes Promote Firm Attachment to Endothelium -- 3.3 Transendothelial Migration -- 3.4 Endothelial Cells Death: A Perfect Gap for Extravasation -- 4 Cellular Plasticity During Extravasation -- 4.1 Invadopodium Development -- 4.2 Endothelial-Mesenchymal Transition -- 5 Intercellular Communication in Extravasation -- 5.1 Cell-Cell Contact: Gap Junctions -- 5.2 Chemical Molecules -- 5.3 Extracellular Vesicles and miRNAs -- 6 Current Models for Cancer Cells Extravasation Study -- 6.1 In Vitro Models: Two-Dimensional (2D) -- 6.2 In Vitro Models: Three-Dimensional (3D) -- 6.3 In Vivo Models -- 7 Extravasation-Targeted Therapies -- 8 Conclusion -- References -- Turn in Breast Cancer Care: Upregulation of Estrogen Signal May Be Much More Effective than Its Inhibition -- 1 Introduction -- 2 Ambiguous Results of Menopausal Hormone Therapy Strengthened the Principle of Estrogen-Induced Cancer -- 3 Searching for the Mechanism of Estrogen-Induced Carcinogenesis -- 4 Estrogen Deficiency and ER Resistance Were Revealed as Cancer Risk Factors -- 5 Crucial Role of Estrogens, ERs, and Estrogen-Regulated Genes in Mammalian Health. 6 Correlations Among Defects of Estrogen Signaling, Breast Cancer Risk, ER Expression, and the ESR1 Gene Status of Tumors -- 7 Molecular Mechanisms Behind Successes and Failures of Antiestrogen Therapy -- 8 Conclusion -- References -- Role of Membrane Estrogen Receptor (GPER1) on the Function of Immune Cells and Its Consequences on Breast Cancer Pathophysiolo... -- 1 Introduction -- 2 Characteristics of GPER1 in Breast Cancer -- 3 Immune Infiltration in Breast Cancer -- 4 Expression and Function of GPER1 by Cells of the Immune System -- 5 Neutrophils -- 6 Eosinophils -- 7 Mast Cells -- 8 Monocytes/Macrophages -- 9 NK Cells -- 10 T Lymphocytes -- 11 B Lymphocytes -- 12 Future Perspectives in GPER Immunity-Related Research and Therapeutic Strategies -- 13 Conclusion -- References -- The Effect of Dietary n-3 Polyunsaturated Fatty Acids on Non-obese and Obesity-Associated Breast Cancer -- 1 Introduction -- 2 n-3 and n-6 Polyunsaturated Fatty Acids (PUFA) -- 3 Relationship Between n-3 PUFA and BC: Evidence in Humans -- 4 Relationship Between n-3 PUFA and BC: Evidence in Animal Models and Mammary Tumor Cell Lines -- 5 Anticarcinogenic Mechanisms of n-3 PUFA -- 6 Obese BC and n-3 PUFA -- 7 Conclusion -- References -- The Role of Soy and Its Isoflavones in Breast Cancer: Beneficial or Harmful? -- 1 Introduction -- 1.1 Breast Cancer Overview -- 1.2 The Importance of Estrogen in the Pathophysiology of Breast Cancer -- 1.3 Soy Foods, Soybeans, and Isoflavones: Pharmacokinetics -- 1.4 Relationship Between Isoflavones and Breast Cancer Risk -- 1.5 The Role of Isoflavones in Modulating Breast Cancer Prognosis and Therapeutic Response -- 1.6 Interpreting the Controversy Regarding Isoflavones and Breast Cancer -- 2 Conclusion -- References -- Mammographic Breast Density and Utility in Breast Cancer Screening and Clinical Decision-Making -- 1 Introduction. 2 Breast Density, Mammographic Appearance, and Measurement -- 3 Mammographic Breast Density and Breast Cancer Risk -- 4 Breast Density and Interval Cancer -- 5 Breast Density and Breast Cancer Detection -- 6 Breast Density and Supplemental Breast Imaging -- 7 Breast Density, Mammography Screening Recall Rate, and Outcome of Recall -- 8 Breast Density, Diagnostic Efficacy of Imaging Assessment Tools, and Biopsy Recommendation and Outcomes -- 9 Breast Density as a Modifiable Component of the Breast -- 10 Breast Density as a Marker of Breast Cancer Prognosis and Treatment Outcome -- 11 Conclusion -- References -- Advanced 3D In Vitro Models to Recapitulate the Breast Tumor Microenvironment -- 1 Introduction -- 2 Towards the Recapitulation of the Breast TME: 3D In Vitro Models -- 3 Hydrogels as Advanced Breast Cancer Models -- 4 (Micro)engineering Approaches to Recapitulate the Breast TME with Hydrogels -- 5 Main Biomaterials Used to Recreate the ECM -- 5.1 Polysaccharides -- 5.1.1 Alginate -- 5.1.2 Hyaluronic Acid -- 5.1.3 Chitosan -- 5.2 Synthetic Polymers -- 5.2.1 Poly(ethylene Glycol) -- 5.2.2 Polyesters -- 5.2.3 Other Synthetic Biopolymers -- 5.3 Proteins -- 5.3.1 Collagen -- 5.3.2 Gelatin -- 5.3.3 Other Proteins -- 5.4 Synthetic Peptides -- 5.5 Native ECM -- 5.5.1 Matrigel -- 5.5.2 Cell-Derived Extracellular Matrices -- 5.5.3 Tissue-Derived Matrices -- 6 Conclusion and Future Perspectives -- References -- Breast Cancer Metastasis to Bone: Look into the Future -- 1 Introduction -- 2 Bone Metastases -- 3 Biomarkers of Breast Metastatic Disease -- 4 Epithelial to Mesenchymal and Mesenchymal to Epithelial Transition -- 5 The Breast Osteoblast-Like Cells -- 6 Role of Exosomes in Breast Cancer Progression -- 7 From Traditional Therapy to the Theragnostic Approach in Bone Metastatic Breast Cancer Treatment. 8 Emerging Therapies and Clinical Trials for Metastatic Breast Cancer -- 9 Conclusion -- References -- Breast Cancer: The Fight for Survival Is Won: What Is the Evidence for Preserving Fertility? -- 1 Introduction -- 2 Epidemiology -- 3 Gonadotoxicity of Breast Cancer Chemotherapy and Radiotherapy -- 3.1 Chemotherapy -- 3.2 Radiotherapy -- 4 Oncofertility -- 4.1 Fertility Counseling -- 4.2 Psychological Aspects of Oncofertility Counseling in Cancer Patients -- 5 Fertility Preservation Techniques -- 5.1 Controlled Ovarian Stimulation (COS) Protocols -- 5.1.1 Mechanism of the Procedure -- 5.1.2 COS Methods Implemented in Cancer Patients -- What Is the Evidence of Fertility Preservation in Breast Cancer? -- 5.1.3 Ovarian Stimulation Protocols in Breast Cancer -- 5.2 Oocyte and Embryo Cryopreservation -- 5.3 In-Vitro Maturation (IVM) -- 6 Time to Get Pregnant -- 7 Conclusion -- References -- Breast Cancer and Pregnancy: Challenges for Maternal and Newborn Successful Outcomes -- 1 Introduction -- 2 Epidemiology -- 3 Diagnosis -- 3.1 Imaging Diagnostics -- 3.2 Pathological Diagnostics -- 4 Staging -- 4.1 Fetal Radiation Exposure -- 5 Treatment -- 5.1 Chemotherapy (Systemic Therapy) -- 5.1.1 Symptom Management -- 5.2 Surgical Treatment -- 5.3 Radiotherapy -- 5.4 Endocrine Therapy -- 5.5 Metastatic Setting -- 6 Obstetric View -- 6.1 Prenatal Care -- 6.2 Additional Workup -- 6.3 Childbirth -- 6.4 Breastfeeding -- 6.5 Surgery During Pregnancy -- 7 Conclusion -- References -- Computer-Aided Approach for BI-RADS Breast Density Classification: Multicentric Retrospective Study -- 1 Introduction -- 2 Background -- 3 Materials and Methods -- 3.1 Software -- 3.2 Data Collection -- 3.3 Ground Truth -- 3.4 Statistical Analysis -- 4 Results -- 5 Discussion -- 5.1 Limitations -- 6 Conclusion -- References. Correction to: Mammographic Breast Density and Utility in Breast Cancer Screening and Clinical Decision-Making. |
| Record Nr. | UNINA-9910874682603321 |
|
Rezaei Nima
|
||
| Cham : , : Springer, , 2024 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Breast Cancer Treatment
| Breast Cancer Treatment |
| Autore | Rezaei Nima |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing AG, , 2024 |
| Descrizione fisica | 1 online resource (445 pages) |
| Collana | Interdisciplinary Cancer Research Series |
| ISBN |
9783031658273
9783031658266 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Preface -- Contents -- About the Editor -- Signal Transducer and Activator of Transcription as a Potential Therapeutic Target in Breast Cancer -- 1 Introduction -- 2 STAT Family Members Characteristics, Activation, and Functional Development -- 2.1 STAT Family Members Expression and Activity in Breast Cancer -- 2.2 STAT1 and Breast Cancer -- 2.3 STAT2 and Breast Cancer -- 2.4 STAT3 and Breast Cancer -- 2.5 STAT4 and Breast Cancer -- 2.6 STAT5a/b and Breast Cancer -- 2.7 STAT6 and Breast Cancer -- 2.8 ER+ Breast Cancer Subtypes and STAT Signaling -- 2.9 HER2/Neu + Breast Cancer and STAT Signaling -- 2.10 TNBC and STAT Signaling -- 3 STAT Proteins: The Promising Targets in the Treatment of Breast Cancer -- 4 Conclusion -- References -- Triple-Negative Breast Cancer Therapy: Recent Advances, Challenges, and Future Perspective -- 1 Introduction -- 2 Predictive Biomarkers, TILs, Genes and Their Roles in TNBC -- 3 Drug Resistance in TNBC -- 4 Systemic Therapy in TNBC -- 5 siRNA Therapy in TNBC -- 6 Conclusion -- References -- Advances in Local Ablative Techniques for Breast Cancer -- 1 Introduction -- 2 Overview of Local Ablative Techniques in Breast Cancer Management -- 3 Localization Techniques -- 4 Ablative Treatment Modalities for Curative Intent -- 4.1 Cryotherapy -- 4.2 Radiofrequency Ablation (RFA) in Breast Cancer Management -- 4.3 High-Intensity Focused Ultrasound (HIFU) -- 4.4 Microwave Ablation -- 4.5 Laser Therapy in Breast Cancer Management -- 5 Ablative Surgery in Palliative Settings -- 5.1 Local Therapy -- 5.2 Ablative Therapies Toward Metastatic Lesion(s) -- 5.2.1 Bone -- 5.2.2 Liver -- 5.2.3 Lung -- 5.2.4 Others -- 6 Conclusion -- References -- Radiotherapy in Breast Cancer -- 1 Introduction -- 2 History -- 3 Overview of Breast Cancer -- 3.1 Types -- 3.2 Breast Cancer Subtypes -- 3.2.1 Hormone Receptor-Positive Breast Cancer.
3.2.2 HER2-Positive Breast Cancer -- 3.2.3 Triple-Negative Breast Cancer -- 3.3 Risk Factors and Etiology -- 3.4 Pathophysiology -- 3.5 Signs and Symptoms -- 3.6 Diagnosis -- 3.7 Staging -- 3.8 Prognosis -- 4 Types of Radiation Therapy -- 5 Uses of Radiotherapy in Breast Cancer -- 6 Brachytherapy -- 7 Combination Therapy and Management of Breast Cancer -- 7.1 Chemotherapy -- 7.2 Targeted Therapy -- 7.3 Management of Non-invasive (In Situ) Breast Cancer -- 7.4 Management of Early Invasive Breast Cancer -- 7.5 Loco-Regional Radiotherapy -- 7.6 Axillary Radiotherapy -- 8 Adverse Effects of Radiation Therapy -- 9 Conclusion -- References -- Percutaneous Breast Cancer Treatment -- 1 Introduction -- 2 Cryoablation -- 3 Radiofrequency Ablation -- 4 Microwave Ablation -- 5 High-Intensity Focused Ultrasound (HIFU) -- 6 Laser Ablation -- 7 Conclusion -- References -- Revolutionizing Breast Cancer Care: Cutting-Edge Breakthroughs and Future Frontiers in Precision Medicine -- 1 Introduction -- 2 Targeted Therapies -- 2.1 Hormone Receptor-Targeted Therapies -- 2.2 HER2-Targeted Therapies -- 2.3 Cell Cycle-Targeted Therapies -- 3 Immunotherapy -- 3.1 Immune Checkpoint Inhibitors -- 3.2 Cancer Vaccines -- 4 Precision Medicine -- 5 Other Emerging Therapies -- 5.1 Oncolytic Viruses -- 5.2 PARP Inhibitors -- 6 Personalized Treatment Approaches -- 6.1 Integration of Genomic and Clinical Data -- 6.2 Development of Decision Support Tools -- 7 Nanotechnology in Breast Cancer Treatment -- 7.1 Folic Acid-Engineered Nanocarriers -- 7.2 Antineoplastic Biogenic Gold Nanoparticles -- 7.3 Lipid-Based Nanoparticles (LNPs) -- 7.4 Curcumin Nanoparticles -- 7.5 Antibody-Conjugated Polymeric Nanoparticles -- 8 Other Treatment Strategies -- 8.1 Liquid Biopsies -- 8.2 Artificial Intelligence -- 9 Role of Modern Bioinformatics in the Treatment of Breast Cancer. 10 Role of CRISPR Gene Editing in Treating Breast Cancer -- 11 Conclusion -- References -- Updates on the Management of Ductal Carcinoma In Situ of the Breasts -- 1 Introduction -- 2 Breast Cancer Screening and Diagnosis of DCIS -- 3 Classification Systems of DCIS -- 4 Challenges in Histopathological Diagnosis -- 5 Paradigm Change of the Current Standard of Care -- 6 Treating DCIS or Treating Patients with DCIS? -- 7 Clinical Factors to Be Considered When Treating Low-Risk DCIS -- 8 Conclusion -- References -- Nanostructured Lipid Carrier as a Strategy for the Treatment of Breast Cancer -- 1 Introduction -- 2 Conventional Treatment of Breast Cancer -- 2.1 Lipidic Nanoparticle as a Strategy for the Treatment of Breast Cancer -- 2.2 Nanostructured Lipid Carriers as a Strategy for the Treatment of Breast Cancer -- 3 Cancer Drug-Loaded NLC -- 3.1 Anthracycline-Loaded NLC as a Strategy for the Treatment of Breast Cancer -- 3.2 Taxane-Loaded NLC as a Strategy for the Treatment of Breast Cancer -- 3.3 Antagonist of Estrogen Receptor-Loaded NLC as a Strategy for the Treatment of Breast Cancer -- 3.4 HIT, LEAD, or Drug Candidate-Loaded NLC as a Strategy for the Treatment of Breast Cancer -- 3.5 Multidrug-Loaded NLC as a Strategy for the Treatment of Breast Cancer -- 3.6 Developing Theory -- 3.7 Stimuli-Responsive NLC as a Strategy for the Treatment of Breast Cancer -- 4 New Trends: Functionalized CLN -- 5 Conclusion -- References -- Managing Breast Cancer Using the Cell-Surface GRP78 -- 1 Introduction -- 1.1 Targeting GRP78 for Early Detection and Diagnosis -- 1.2 Modulating GRP78 Expression for Therapeutic Intervention -- 1.3 GRP78 as a Prognostic Indicator and Monitoring Tool -- 1.4 GRP78 Mediates Cell Survival and Apoptosis -- 1.5 Challenges and Future Prospects -- 2 Conclusion -- References. A Hormone Immunotherapy (HIT) Combination in Advanced Breast Cancer -- 1 Introduction -- 2 Current Guidelines for HT, IT, and Their Combination in Advanced Breast Cancer -- 2.1 Systemic Therapy in the Adjuvant Setting (Table 1) -- 2.2 Systemic Therapy in Locoregional Recurrent or Stage IV (M1) Breast Cancer (Table 2) -- 3 Experimental Studies Suggest a Close Relationship Between Tumor Growth and the G0-G1 State and Immune Evasion -- 3.1 Tumor Growth and Immune Evasion -- 3.2 G0-G1 State and Immunosuppressive TME Reversion Induced by Antiestrogens -- 4 Usefulness of Maintenance IT in Patients Showing Clinical Benefit During Conventional CT or with Minimal Residual Disease (M... -- 5 A Prolonged Antiestrogen-Induced G0-G1 State Concomitant with an Increased Cytotoxic Immune Response During a New Schedule o... -- 6 The Potential Rationale of a New HIT Schedule -- 7 Conclusion -- References -- Discovering New Targets in Triple-Negative Breast Cancer (TNBC): The Androgen Receptor and the Estrogen Receptor β -- 1 Introduction -- 2 Triple-Negative Breast Cancer -- 2.1 TNBC Therapies -- 2.2 Targeted Therapies -- 2.3 Immunotherapy -- 2.4 AR in Triple-Negative Breast Cancer -- 2.4.1 AR: Structure and Function -- 2.4.2 AR in Breast Cancer: An Overview -- 2.4.3 The Role of AR in TNBC -- 2.4.4 Androgen Targeted Therapies -- 2.5 Estrogen Receptor β in Triple-Negative Breast Cancer -- 2.5.1 Estrogen Receptor β: Generalities -- 2.5.2 The Role of ERβ in BC: An Overview -- 2.5.3 The Role of ERβ in Triple-Negative Breast Cancer -- 2.5.4 Estrogen Receptor β Targeted Therapy in TNBC -- 3 Concluding Remarks -- References -- Growth Factor Receptor Implications in Breast Cancer: Prospects for Their Molecular Transactivation in the Future and Obstacle... -- 1 Introduction -- 1.1 Incidence -- 1.2 Risk Factors -- 2 Definition and Molecular Classification of BC. 2.1 BC Classification -- 2.2 Histological Subtypes -- 2.3 Molecular Subtypes -- 2.4 Estrogen Receptor (ER) -- 2.5 Nuclear ER -- 2.6 Membranal ER -- 2.7 Relationship Between ER and HER2 -- 3 Receptor Tyrosine Kinases -- 3.1 Structure and Classification -- 3.2 Role of Receptor Tyrosine Kinase (RTK) Signaling in BC Progression: MAPKs and PI3K/Akt Signaling Pathways -- 3.2.1 Signaling Pathways -- 3.2.2 Mitogen-Activated Protein Kinase Pathway (MAPK) -- 3.2.3 ERK Cascade -- 3.2.4 JNK Cascade -- 3.2.5 p38 Cascade -- 3.2.6 Phosphoinositide 3-Kinase/Akt Pathway (PI3K/Akt) -- 3.2.7 Janus Kinase/Signal Transducer and Activator of Transcription Pathway (JAK/STAT) -- 3.2.8 Notch Signaling Pathway -- 3.2.9 Nuclear Factor-Kappa B Pathway (NF-κB) -- 3.2.10 Src Family Kinases -- 4 Participation of Specific RTKs in BC -- 4.1 RTKs and BC -- 4.2 Role of Epidermal Growth Factor Receptor (EGFR) in BC -- 4.3 Role of HER2 in BC -- 4.4 Role of Insulin Receptor (IR) in BC -- 4.5 Role of Insulin-Like Growth Factor Receptor Type 1 (IGF-1R) in BC -- 4.6 Role of Vascular Endothelial Growth Factor Receptor (VEGR) in BC -- 4.7 Role of Platelet-Derived Growth Factor Receptor (PDGFR) in BC -- 4.8 Role of Fibroblast Growth Factor Receptor (FGFR) in BC -- 4.9 Role of Hepatocyte Growth Factor (HGF)/MET Receptor in BC -- 5 RTK Transactivation by GPCRS and Nuclear Receptors -- 5.1 GPCRs -- 5.2 GPCR-Mediated Transactivation of RTKs -- 5.3 GPCRS in Cancer and BC -- 5.4 RTK Transactivation by Specific GPCRs in BC -- 5.4.1 Estrogens/GPER1 -- 5.4.2 Chemokine Receptors -- 5.4.3 Cannabinoid Receptor 2 -- 5.4.4 Lysophosphatidic Acid (LPA) Receptors (LPARs) -- 5.4.5 Protease-Activated Receptors -- 6 Blocking GPCRS-RTKs Transactivation, Therapeutic Strategies with a Clinical Approach -- References -- Addressing ESR1 Mutation: A Key Factor in Hormone Therapy Resistance in Breast Cancer. 1 Introduction. |
| Record Nr. | UNINA-9910874667903321 |
|
Rezaei Nima
|
||
| Cham : , : Springer International Publishing AG, , 2024 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cancer Research: An Interdisciplinary Approach / / edited by Nima Rezaei
| Cancer Research: An Interdisciplinary Approach / / edited by Nima Rezaei |
| Autore | Rezaei Nima |
| Edizione | [1st ed. 2023.] |
| Pubbl/distr/stampa | Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2023 |
| Descrizione fisica | 1 online resource (614 pages) |
| Disciplina | 616.9940072 |
| Collana | Interdisciplinary Cancer Research |
| Soggetto topico |
Cancer
Cancer—Treatment Stem cells Cytology Medical genetics Immunology Cancer Biology Cancer Therapy Cancer Stem Cells Cell Biology Medical Genetics |
| ISBN | 3-031-32458-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Interdisciplinary Approaches in Cancer Research -- Role of Immune Cells in the Tumor Microenvironment -- Spatial Transcriptomic Approaches for Understanding the Tumor Microenvironment (TME) -- Role of Mesenchymal Stem/Stromal Cells in Cancer Development -- Cancer-associated Fibroblasts and Their Role in Cancer Progression -- The Role of Tumoroids in Cancer Research -- Myokines Expression in Cancer Cachexia -- Epigenetics in Cancer Biology -- Epigenetic Regulation of Cancer by Natural Touch: Phytochemicals and Epigenetic Regulation -- Telomerase Reverse Transcriptase in Humans: From Biology to Cancer Immunity -- Molecular Mechanisms of Metal-induced Carcinogenesis -- Epi-drugs Targeting RNA Dynamics in Cancer -- Oncologic Emergencies: Pathophysiology, Diagnosis, and Initial Management -- Malignancies in Inborn Errors of Immunity -- Hematopoietic Stem Cell Transplantation in Patients with Inborn Errors of Immunity and Malignancy -- Personalized Immuno-oncology with Immunodeficiency Mouse Models -- Allergy and Cancer: New Perspectives -- Depression and Cancer: the Inflammatory Bridge -- Impact of Cancer-Related Sarcopenia on Systemic Immune Status -- Surveillance of Subclinical Cardiovascular Complications in Childhood Cancer Survivors: Exercise as a Diagnostic and Therapeutic Modality. |
| Record Nr. | UNINA-9910734848103321 |
|
Rezaei Nima
|
||
| Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2023 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Gastrointestinal Cancers: An Interdisciplinary Approach [[electronic resource] /] / edited by Nima Rezaei
| Gastrointestinal Cancers: An Interdisciplinary Approach [[electronic resource] /] / edited by Nima Rezaei |
| Autore | Rezaei Nima |
| Edizione | [1st ed. 2023.] |
| Pubbl/distr/stampa | Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2023 |
| Descrizione fisica | 1 online resource (405 pages) |
| Disciplina |
571.978
616.994 |
| Collana | Interdisciplinary Cancer Research |
| Soggetto topico |
Cancer
Cancer - Treatment Oncology Immunotherapy Tumors - Immunological aspects Nanomedicine Gastrointestinal Neoplasms Tumor Microenvironment Cancer Biology Cancer Therapy Tumour Immunology Cancer Nanotechnology |
| ISBN | 3-031-48371-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Interdisciplinary Approach in Gastrointestinal Cancers -- Gastrointestinal Cancers: What Is the Real Board of Microenvironment and the Role of Microbiota-Immunity Axis -- Epithelial-Mesenchymal Transition in Gastrointestinal Cancer: From a Basic to a Clinical Approach -- Metabolomics of Gastrointestinal Cancers -- Deregulation of Immune System in Gastric Cancer Development, How Immune Nutrition Might Restore the Functions of Immune Cells -- Helicobacter pylori Virulence Factors, Pathogenicity, and Gastric Cancer -- Gastric Cancer and Helicobacter pylori -- Role of Neuromodulators in Regulation of the Tumor Microenvironment of Gastric and Colorectal Cancers -- The Role of Tumor Microenvironment in Colon Cancer -- Unraveling the Esophageal Cancer Tumor Microenvironment: Insights and Novel Immunotherapeutic Strategies -- The Interplay Between Immunity and Gut Microbiota in Colon Cancer -- Immunotherapy in Gastrointestinal Cancer Focusing on CAR-T Cell Therapy -- Development of Biocompatible Nanocarriers for the Treatment of Colorectal Cancer -- Challenges of Onco-therapeutics in Early Onset Colorectal Cancer -- Unintentional Weight Loss and Malnutrition After Esophageal Cancer and Treatment -- Current Clinical Landscape of Immunotherapeutic Approaches in Pancreatic Cancer Treatment. The Tumor Microenvironment in Pancreatic Cancer and Challenges to Immunotherapy. . |
| Record Nr. | UNINA-9910799498103321 |
|
Rezaei Nima
|
||
| Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2023 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Human Brain and Spinal Cord Tumors: From Bench to Bedside. Volume 2 : The Path to Bedside Management / / edited by Nima Rezaei, Sara Hanaei
| Human Brain and Spinal Cord Tumors: From Bench to Bedside. Volume 2 : The Path to Bedside Management / / edited by Nima Rezaei, Sara Hanaei |
| Autore | Rezaei Nima |
| Edizione | [1st ed. 2023.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2023 |
| Descrizione fisica | 1 online resource (754 pages) |
| Disciplina | 616.9948061 |
| Altri autori (Persone) | HanaeiSara |
| Collana | Advances in Experimental Medicine and Biology |
| Soggetto topico |
Medicine—Research
Biology—Research Neurology Internal medicine Immunology Spinal Cord Neoplasms Brain Neoplasms Biomedical Research Internal Medicine |
| ISBN | 3-031-23705-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Chapter 1. Malignant Glioma -- Chapter 2. Benign Glioma -- Chapter3. Meningioma and Other Meningeal Tumors -- Chapter4. Epondymomas in Pediatric and Adults -- Chapter5. Medulloblastomas in Pediatric and Adults -- Chapter6. Benign and Malignant Tumors of The Pineal Region -- Chapter7. The Tumors of Choroid Plexus and Other Ventricular Tumors -- Chapter8. Embryonal Tumors of The Central Nervous System with Multilayered Rosettes and Atypical Teratoid/Rhabdoid Tumors -- Chapter9. Glioneuronal and Neuronal Tumors of the Central Nervous System -- Chapter10. Benign and Malignant Tumors of the Pituitary Gland -- Chapter11. Craniopharyngioma in Pediatric and Adults -- Chapter12. Schwannomas of Brain and Spinal Cord -- Chapter13. Other Nerve-Sheet Tumors of Brain and Spinal Cord -- Chapter14. Hemangioblastomas and Other Vascular Originating Tumors of Brain or Spinal Cord -- Chapter15. Brain and Spinal Cord Tumors of Embryonic Origin -- Chapter16. Brain and Spinal Tumors Originating from the Germ Line Cells -- Chapter17. Benign Brain and Spinal Tumors Originating from Bone or Cartilage -- Chapter18. Benign Spinal Tumors -- Chapter19. Other Less Prevalent Tumors of the Central Nervous System -- Chapter20. Brain and/or Spinal Cord Tumors Accompanied with Other Diseases or Syndromes -- Chapter21. Psychological and Psychiatric Aspects of Brain and Spinal Cord Tumors -- Chapter22. A Brief Explanation on Surgical Approaches for Treatment of Different Brain Tumors. |
| Record Nr. | UNINA-9910734875803321 |
|
Rezaei Nima
|
||
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2023 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Lung Cancer Pathophysiology
| Lung Cancer Pathophysiology |
| Autore | Rezaei Nima |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing AG, , 2024 |
| Descrizione fisica | 1 online resource (272 pages) |
| Collana | Interdisciplinary Cancer Research Series |
| ISBN |
9783031661525
9783031661518 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Preface -- Contents -- About the Editor -- Interdisciplinary Approach in Lung Cancers -- 1 Introduction -- 2 Epidemiology -- 3 Screening -- 4 Clinical Manifestations and Diagnosis -- 5 Classification -- 6 Treatment -- 7 Conclusion -- References -- Fundamental Elements of a High-Functioning Lung Cancer Multidisciplinary Team (MDT) -- 1 Introduction -- 1.1 Multidisciplinary Team -- 1.2 Leadership -- 1.3 Team Collaboration -- 1.4 The MDT Venue -- 1.5 Data -- 1.6 MDT Billing -- 1.7 Biobank -- 1.8 Research -- 2 Conclusion -- References -- Epithelial to Mesenchymal Transition in Lung Cancer: When It Starts? -- 1 Introduction: EMT in Early-Stage Lung Cancer -- 2 EMT Phenotype in Early-Stage Lung Cancer -- 2.1 Regulatory Genes of EMT in Early-Stage Lung Cancer -- 2.2 Circulating Tumor Cells in Early-Stage EMT in Lung Cancer -- 2.3 Lymph Node Status and Phenotypic Transition in Early-Stage EMT -- 3 The Roles of ncRNA in EMT Regulation in Early-Stage Lung Cancer -- 3.1 miRNAs in EMT Regulation in Lung Cancer -- 3.2 lncRNAs in EMT in Early-Stage Lung Cancer -- 4 EMT as Mechanisms of Resistance to Conventional and Targeted Therapies in Lung Cancers: Correlations with Different Treatmen... -- 4.1 Adjuvant Treatment Setting as a Potential Early Time Point for EMT -- 4.2 First-Line Treatment of Advanced and Metastatic Lung Cancer Harboring Actionable Mutations as a Potential Early Time Point... -- 5 Conclusion -- References -- Roles of Tumor Immune Microenvironment in Non-small Cell Lung Cancer -- 1 Introduction -- 2 Interaction Between Tumor and TIME -- 2.1 Tumor Intrinsic Factors -- 2.1.1 Immunogenic Hot Tumors -- 2.1.2 Immunosuppressive Cold Tumors -- 2.1.3 Premalignant Lesions -- 2.2 Immune Contexture -- 2.2.1 T Lymphocytes -- 2.2.2 B Lymphocytes -- 2.2.3 Natural Killer Cells -- 2.2.4 Macrophages -- 2.2.5 Neutrophils -- 2.2.6 Dendritic Cells.
2.2.7 Myeloid-Derived Suppressor Cells (MDSCs) -- 3 Tertiary Lymphoid Structures (TLSs) -- 4 TNM-I: TNM-Immunoscore in NSCLC -- 4.1 Location and Compartments of Immune Cells Within the Tumor -- 4.2 Scoring Method: Manual or Digital? -- 4.3 Whole Slides or Tissue Microarrays -- 5 Conclusion -- References -- Natural Killer Cells in Lung Cancer -- 1 Introduction -- 1.1 Non-small-cell Lung Cancer -- 1.2 Small-Cell Lung Cancer -- 2 Natural Killer Cells -- 2.1 Development and Maturation -- 2.2 NK Cell Cytotoxicity -- 3 Natural Killer Cells and Lung Cancer -- 3.1 NK Cell-Based Immunotherapies in Lung Cancer -- 4 Conclusion -- References -- RNA-binding Proteins as a New Link Between COPD and Lung Cancer -- 1 Introduction -- 2 RNA-binding Proteins (RBPs) as Mediator of Post-transcriptional Gene Regulation (PTGR) -- 3 RBPs in COPD Pathogenesis -- 4 RBPs in Modulating the Inflammation of Lower Airways -- 5 RBPs in Modulating IL-33 Signaling Pathway and COPD -- 6 RBPs in Modulating Drugs Response in COPD -- 7 RBPs in Lung Cancer Pathogenesis -- 8 Non-small Cell Lung Cancer (NSCLC) -- 9 Small Cell Lung Cancer (SCLC) -- 10 RBPs in Modulating IL-33 Signaling Pathway and Lung Cancer -- 11 The Role of RBPs in Mechanisms Linking COPD and Lung Cancer -- 12 Conclusion -- References -- The Implication of miRNA Signature in the Characteristic Features and Diagnosis of Lung Cancer -- 1 Introduction -- 1.1 Lung Cancer -- 1.2 MicroRNA -- 1.3 Biogenesis of miRNA -- 2 Impact of miRNA Signatures in Targeting the Various Characteristics of LC -- 2.1 Sustaining Proliferative Signaling in LC -- 2.2 Evading Growth Suppressors in LC -- 2.3 Resisting Cell Death in LC -- 2.4 Enabling Replicative Immortality in LC -- 2.5 Inducing Angiogenesis -- 2.6 Activating Invasion and Metastasis in LC -- 2.7 Deregulating Cellular Energetic in LC -- 2.8 Avoiding Immune Destruction in LC. 2.9 Tumor-Promoting Inflammation -- 2.10 Genome Instability and Mutation -- 3 MicroRNA as Diagnostic Markers in LC -- 3.1 Biomarkers -- 3.2 miRNA as Noninvasive Diagnostic Markers -- 3.3 miRNA as Biomarker in Histological Subtype Identification -- 3.4 miRNA as a Biomarker in the Differentiation of Tumors -- 4 Conclusion and Perspectives -- References -- MicroRNAs in the Immunopathology and Treatment of Non-small Cell Lung Cancer -- 1 Introduction -- 1.1 Statistics of NSCLC -- 2 sncRNAs in Development of NSCLC -- 3 sncRNAs as Markers of Efficacy of Treatment -- 4 Surgery -- 5 Radiotherapy -- 6 Chemotherapy -- 6.1 Platinum Derivatives -- 6.2 Taxanes -- 7 Immune Therapy -- 7.1 Immunopathology of NSCLC -- 7.2 EGFR -- 7.3 PD/PD-L1 -- 7.4 CTLA-4 -- 8 MicroRNA-Based Therapy -- 8.1 Application Schemas -- 9 Side Effects and Complications -- 9.1 Conventional Therapy -- 9.2 MicroRNA-Based Therapy -- 10 Conclusion -- References -- Monitoring Exosomal Non-coding RNA in Lung Cancers -- 1 Introduction -- 2 Non-coding RNAs -- 2.1 MicroRNAs -- 2.2 Long Non-coding RNAs -- 3 Exosomes -- 3.1 Exosome Biogenesis -- 3.2 Exosomes Cargo -- 3.3 Exosomes in Cancer -- 4 Non-coding RNAs as Biomarkers in Lung Cancer -- 4.1 Exosome-Derived miRNAs and Lung Cancer Proliferation -- 4.2 Exosome-Derived miRNAs and Angiogenesis -- 4.3 Exosome-Derived ncRNAs and EMT/MET -- 4.4 Exosomal miRNAs Underlying Cisplatin Resistance -- 5 Exosome-Derived miRNAs and Their Diagnostic and Clinical Relevance -- 6 Conclusion -- References -- Mediastinal Staging of Lung Cancer -- 1 Introduction -- 2 Imaging Techniques -- 3 Non-surgical Techniques: Diagnostic Procedures in Interventional Pulmonology -- 3.1 Transbronchial Needle Aspiration -- 3.2 Endobronchial Ultrasound-TBNA -- 3.3 Esophageal Ultrasound-Guided Fine Needle Aspiration -- 3.4 EBUS-TBNA and EUS-FNA Technique -- 3.5 Samples. 3.6 Safety and Contraindications -- 3.7 Use of Combination Techniques -- 3.8 Transthoracic Needle Aspiration -- 3.9 Lymph Node Cryobiopsy -- 3.10 Rapid On-Site Evaluation -- 3.11 Endobronchial Elastography -- 4 Surgical Techniques -- 4.1 Mediastinoscopy -- 4.2 Transcervical Extended Mediastinal Lymphadenectomy -- 4.3 Video-Assisted Mediastinoscopic Lymphadenectomy -- 4.4 Video-Assisted Thoracic Surgery -- 4.5 Robotic-Assisted Thoracic Surgery -- 5 Restaging After Oncologic Therapy -- 5.1 Imaging -- 5.2 EBUS-TBNA -- 5.3 Surgical Techniques -- 6 Restaging After Surgery -- 7 Conclusion and Future Perspectives -- References -- Pleural Mesothelioma: The Importance of Working Together -- 1 Introduction -- 2 Histopathological Classification -- 3 Genetic Mutations -- 4 Gene Expression Modulation -- 5 Diagnosis -- 6 Treatment -- 7 The Importance of Working Together -- References -- Comprehensive Genomic Profiling in Lung Cancer in the Era of Immunotherapy Approaches: The Role of Molecular Tumour Boards -- 1 Introduction -- 2 Efficacy of Immunotherapy in Advanced NSCLC Patients Harbouring EGFR Mutations or ALK Rearrangement -- 3 Efficacy of Immunotherapy in Advanced NSCLC Patients Harbouring Rare Oncogenic-Driven Alterations: The IMMUNOTARGET Registry -- 4 The Role of Molecular Tumour Boards: Experiences, Strengths and Limits -- 5 Conclusion -- References -- Index. |
| Record Nr. | UNINA-9910874662703321 |
|
Rezaei Nima
|
||
| Cham : , : Springer International Publishing AG, , 2024 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Vaccines for cancer immunotherapy : an evidence-based review on current status and future perspectives / / Nima Rezaei, Mahsa Keshavarz-Fathi
| Vaccines for cancer immunotherapy : an evidence-based review on current status and future perspectives / / Nima Rezaei, Mahsa Keshavarz-Fathi |
| Autore | Rezaei Nima |
| Pubbl/distr/stampa | London, United Kingdom : , : Academic Press, an imprint of Elsevier, , [2019] |
| Descrizione fisica | 1 online resource (185 pages) |
| Disciplina | 616.994061 |
| Soggetto topico | Cancer - Immunotherapy |
| ISBN | 0-12-814040-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front Cover -- Vaccines for Cancer Immunotherapy -- Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives -- Copyright -- Contents -- List of Contributors -- Preface -- 1 - CANCER IMMUNOLOGY -- INNATE AND ADOPTIVE IMMUNITY -- ACTIVATING IMMUNE CELLS -- MATURE DCS -- CLASSICALLY ACTIVATED MACROPHAGES (M1) -- GRANULOCYTES -- B LYMPHOCYTES -- T HELPER LYMPHOCYTES -- CYTOTOXIC T LYMPHOCYTES -- γδ T LYMPHOCYTES -- NATURAL KILLER T CELLS -- NATURAL KILLER CELLS -- INHIBITORY IMMUNE CELLS -- TOLEROGENIC DCS -- ALTERNATIVELY ACTIVATED MACROPHAGES (M2S) -- MYELOID-DERIVED SUPPRESSOR CELLS -- REGULATORY T CELLS -- REGULATORY B CELLS -- IMMUNOEDITING HYPOTHESIS -- ELIMINATION -- Cells -- Interferons -- Perforin -- Tumor Cell Recognition -- EQUILIBRIUM -- ESCAPE -- Defects in Tumor Antigen Processing, Presentation, and Recognition -- Lack of Activating Mechanisms -- Inhibitory Mechanisms and Immunosuppressive State -- Resistant Tumor Cells -- REFERENCES -- 2 - IMMUNOTHERAPEUTIC APPROACHES IN CANCER -- HISTORY -- APPROACHES OF CANCER IMMUNOTHERAPY -- PASSIVE VERSUS ACTIVE IMMUNOTHERAPY -- PASSIVE IMMUNOTHERAPY FOR CANCER -- Cytokines -- Monoclonal Antibodies (mAbs) -- Adoptive Cell Therapy -- ACTIVE IMMUNOTHERAPY FOR CANCER -- Vaccines -- Peptide Vaccine -- Tumor Cell Vaccine -- Dendritic Cell Vaccine -- Genetic Vaccine -- Checkpoint Inhibitors -- Oncolytic Viruses -- MECHANISM-BASED IMMUNOTHERAPIES: INTERACTIONS BETWEEN TUMOR CELLS AND THE IMMUNE SYSTEM -- TUMOR ANTIGEN EXPRESSION, RELEASE AND PRESENTATION -- T CELL PRIMING AND ACTIVATION -- TRAFFICKING AND INFILTRATION OF T CELLS TO TUMOR -- TUMOR CELL RECOGNITION AND EFFECTOR FUNCTION OF T CELLS -- REFERENCES -- 3 - VACCINES, ADJUVANTS, AND DELIVERY SYSTEMS -- DEFINITION AND CLASSIFICATION -- CANCER VACCINE -- PREVENTIVE CANCER VACCINE.
THERAPEUTIC CANCER VACCINE -- ADJUVANTS -- NONSPECIFIC ADJUVANTS -- CYTOKINES AND CHEMOKINES -- STIMULATORS OF THE INNATE IMMUNE SYSTEM -- C-type Lectin Receptor Ligands -- RIG-like Receptor Ligands -- Stimulator of Interferon Gene Ligands -- Toll like Receptor Ligands -- TLR2 Agonists -- TLR3 Agonists -- TLR4 Agonists -- TLR7 and TLR8 Agonists -- TLR9 Agonists -- Other Immunomodulatory Adjuvants -- Adjuvant Systems -- VECTORS AND DELIVERY SYSTEM -- ROUTE OF ADMINISTRATION -- REFERENCES -- 4 - TUMOR ANTIGENS -- INTRODUCTION -- IDENTIFICATION OF TUMOR ANTIGENS -- OVEREXPRESSED PROTEINS AND MUTATED ANTIGENS IN TUMOR CELLS -- EPITOPE SPREADING -- TUMOR-ASSOCIATED ANTIGENS -- TUMOR-SPECIFIC ANTIGENS -- NEOANTIGENS -- GLYCOLIPIDS AND GLYCOPROTEINS AS ANTIGENS -- MONO-EPITOPE VERSUS POLY-EPITOPE ANTIGEN -- REFERENCES -- 5 - STRATEGY OF ALLOGENEIC AND AUTOLOGOUS CANCER VACCINES -- AUTOLOGOUS CANCER VACCINES -- IN VIVO STUDIES AND CLINICAL IMPLICATIONS -- ALLOGENEIC CANCER VACCINES -- IN VITRO/IN VIVO STUDIES AND CLINICAL IMPLICATIONS -- REFERENCES -- 6 - PERSONALIZED CANCER VACCINE -- INTRODUCTION ON PERSONALIZED MEDICINE -- PERSONALIZED MEDICINE IN CANCER PATIENTS -- SCREENING OF CANCER -- CLASSIFICATION OF TUMORS -- TARGETED THERAPY AND USING PREDICTIVE BIOMARKERS -- SAFETY OF MEDICATION -- PROGNOSTIC BIOMARKERS -- NEOANTIGENS AND PERSONALIZED CANCER VACCINES -- PERSONALIZED CANCER VACCINES IN CLINICAL STUDIES -- WHOLE TUMOR CELL VACCINES -- PEPTIDE/PROTEIN-BASED VACCINE -- IMMUNE CELL-BASED VACCINES -- GENETIC-BASED VACCINE -- REFERENCES -- 7 - WHOLE TUMOR CELL VACCINE FOR CANCER -- TUMOR CELL LYSATES -- TUMOR-DERIVED EXOSOMES -- IRRADIATED GENE-MODIFIED TUMOR CELL VACCINE -- CLINICAL TRIALS -- APPROVED VACCINE -- ADVANTAGES AND DISADVANTAGES -- OPTIMIZATION -- REFERENCES -- 8 - PEPTIDE AND PROTEIN VACCINES FOR CANCER -- PEPTIDE-BASED VACCINE. PROTEIN-BASED VACCINE -- MECHANISM OF ACTION -- CLINICAL TRIALS -- PEPTIDE-BASED VACCINE -- Gp100 -- BLP25 -- PROTEIN BASED VACCINE -- MAGE-A3 -- EGF-P64k -- ADVANTAGES AND DISADVANTAGES -- OPTIMIZATION -- REFERENCES -- 9 - IMMUNE CELL VACCINE FOR CANCER -- IMMUNE CELL VACCINE -- MECHANISM OF ACTION -- CLINICAL TRIALS -- IMMATURE DENDRITIC CELLS PULSED WITH TUMOR CELL LYSATES -- MATURE DENDRITIC CELLS PULSED WITH TUMOR CELL LYSATES -- DENDRITIC CELLS LOADED WITH TUMOR-DERIVED RNA -- DENDRITIC CELLS PULSED WITH PEPTIDES -- DENDRITIC CELLS LOADED WITH TUMOR CELLS -- APPROVED VACCINE -- ADVANTAGES AND DISADVANTAGES -- OPTIMIZATION -- REFERENCES -- 10 - GENETIC VACCINE FOR CANCER -- MECHANISM OF ACTION -- MECHANISM OF ACTION OF DNA VACCINES -- MECHANISM OF ACTION OF RNA VACCINES -- DNA VACCINE -- CLINICAL TRIALS -- DELIVERY, IMMUNOGENICITY AND IMMUNE RESPONSE -- ADVERSE EFFECTS -- RNA VACCINE -- CLINICAL TRIALS -- DELIVERY, IMMUNOGENICITY AND IMMUNE RESPONSE -- ADVERSE EFFECTS -- ADVANTAGES AND DISADVANTAGES -- ADVANTAGES AND DISADVANTAGES OF DNA VACCINES -- ADVANTAGES OF RNA VACCINES -- OPTIMIZATION -- DNA VACCINE OPTIMIZATION -- RNA VACCINE OPTIMIZATION -- REFERENCES -- 11 - CANDIDATE CANCERS FOR VACCINATION -- VACCINES FOR PROSTATE CANCER -- VACCINES FOR MELANOMA -- VACCINES FOR LUNG CANCER -- VACCINES FOR COLORECTAL CANCER -- VACCINES FOR BREAST CANCER -- REFERENCES -- 12 - OBSTACLES IN THE DEVELOPMENT OF THERAPEUTIC CANCER VACCINES -- TUMOR ANTIGENS -- TUMOR BURDEN -- CLINICAL RESPONSE VERSUS IMMUNE RESPONSE -- PRIOR TREATMENTS -- DESIGNING CLINICAL TRIALS -- REFERENCES -- 13 - COMBINATION THERAPY: CANCER VACCINES AND OTHER THERAPEUTICS -- CHEMOTHERAPY COMBINED WITH VACCINES -- RADIATION COMBINED WITH VACCINES -- TARGETED THERAPIES COMBINED WITH IMMUNOTHERAPY -- HORMONE THERAPY COMBINED WITH VACCINE. VACCINE COMBINED WITH OTHER IMMUNOTHERAPEUTIC MODALITIES -- REFERENCES -- 14 - CONCLUDING REMARKS AND FUTURE PERSPECTIVES ON THERAPEUTIC CANCER VACCINES -- CONCLUDING REMARKS -- BASIC IMMUNOLOGY OF CANCER VACCINES -- APPROVED VACCINES -- NEOANTIGEN VACCINES -- PREVENTIVE CANCER VACCINE -- CONSIDERATIONS TO FULFILL AMBITIONS -- REFERENCES -- Index -- Back Cover. |
| Record Nr. | UNINA-9910583347503321 |
|
Rezaei Nima
|
||
| London, United Kingdom : , : Academic Press, an imprint of Elsevier, , [2019] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||